Last reviewed · How we verify
NCT03742856
A Multi-omics Study of Epithelial Ovarian Cancer
trial testing A multi-omics analysis in Epithelial Ovarian Cancer in 80 participants. Status unknown.
23 November 2020
Quick facts
| Lead sponsor | Lei Li |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 10 November 2018 |
| Primary completion | 23 November 2020 |
| Estimated completion | 23 November 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- A multi-omics analysis
Conditions studied
- Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
- Tumor Invasiveness — all drugs for Tumor Invasiveness →
- Whole Exome Sequencing — all drugs for Whole Exome Sequencing →
- Transcriptomics — all drugs for Transcriptomics →
Sponsor
Lei Li — full company profile →
Who can join
Eligibility, female only, with Epithelial Ovarian Cancer or Tumor Invasiveness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations.
Zhang XZ, Liu H, Chen SR. · · 2020 · cited 109× · PMID 32429086 · DOI 10.3390/cancers12051245 -
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.
Khan MA, Vikramdeo KS, Sudan SK, Singh S, et al · · 2021 · cited 45× · PMID 34418576 · DOI 10.1016/j.semcancer.2021.08.005 -
Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer.
Shiao MS, Chang JM, Lertkhachonsuk AA, Rermluk N, et al · · 2021 · cited 20× · PMID 34680550 · DOI 10.3390/biomedicines9101433 -
Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer.
Seborova K, Vaclavikova R, Rob L, Soucek P, et al · · 2021 · cited 14× · PMID 33921525 · DOI 10.3390/cancers13081839 -
The Roles of Exosomes in Ovarian Cancer Chemo-resistance.
Liu Y, Li X, Zhang T, Liu G. · · 2023 · cited 9× · PMID 37497408 · DOI 10.7150/jca.84930 -
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.
Bhadra M, Sachan M, Nara S. · · 2024 · cited 8× · PMID 38690293 · DOI 10.3389/fmolb.2024.1361601 -
Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies.
Nair M, Samidurai A, Das A, Kakar SS, et al · · 2025 · cited 3× · PMID 40188339 · DOI 10.1186/s13048-025-01636-z
Verify or expand the search:
- PubMed search for NCT03742856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of A multi-omics analysis
Trials testing the same drug.
- NCT03742869 — HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma · unknown
- NCT03742843 — A Multi-omics Study of Adenomyosis · unknown
Other recruiting trials for Epithelial Ovarian Cancer
Currently open trials in the same condition.
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
- NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
- NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
Other Lei Li trials
Trials by the same sponsor.
- NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
- NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
- NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
- NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
- NCT06490380 — HRD Status Reference Standard Based on WGS · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03742856 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lei Li
- Last refreshed: 15 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03742856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing